Latest News and Events
Filter by
Selections
January 22, 2018
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
Read MoreJanuary 18, 2018
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Read MoreJanuary 17, 2018
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
Read MoreDecember 27, 2017
Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors
Read MoreDecember 22, 2017
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV
Read MoreDecember 20, 2017
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
Read MoreDecember 18, 2017